A Study to Assess IPN01194 in Adults With Advanced Solid Tumours
Phase 1/2
220
about 4 years
18+
5 sites in CA, CT, TN +1
What this study is about
This trial is testing a treatment called IPN01194 in adults with advanced solid tumors. The goal is to determine the right dose, safety, and effectiveness of IPN01194.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IPN01194
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1: Percentage of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TE SAEs), Phase 1: Percentage of participants with dose limiting toxicity (DLT), Phase 2a: Objective response rate (ORR)
Secondary: Phase 1: Geometric mean ratio of Cmax of IPN01194 administered in fed state relative to fasted state, Phase 1: Maximum observed drug concentration (Cmax) after single and multiple doses of IPN01194, Phase 1: Objective response rate (ORR), Phase 1: Time to maximum observed drug concentration (Tmax) after single and multiple doses of IPN01194, Phase 2a: Disease control rate (DCR), Phase 2a: Duration of response (DoR), Phase 2a: PFS rate at 4 months, Phase 2a: Percentage of participants with TEAEs and TE SAEs
Oncology